Other equities research analysts also recently issued reports about the stock. Jefferies Group LLC restated a buy rating and issued a GBX 5,400 ($69.70) target price on shares of AstraZeneca plc in a research note on Friday, January 13th. Bryan, Garnier & Co restated a buy rating and issued a GBX 5,250 ($67.77) target price on shares of AstraZeneca plc in a research note on Monday, January 9th. Morgan Stanley set a GBX 5,600 ($72.29) price target on shares of AstraZeneca plc and gave the stock a buy rating in a report on Wednesday, January 18th. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 6,000 ($77.45) price target on shares of AstraZeneca plc in a report on Wednesday, January 18th. Finally, Kepler Capital Markets reaffirmed a buy rating and issued a GBX 5,000 ($64.54) price target on shares of AstraZeneca plc in a report on Monday, January 23rd. Five investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of GBX 5,001.80 ($64.56).
Shares of AstraZeneca plc (LON:AZN) opened at 5119.00 on Thursday. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The stock has a 50 day moving average price of GBX 4,801.40 and a 200 day moving average price of GBX 4,560.72. The stock’s market capitalization is GBX 64.81 billion.
TRADEMARK VIOLATION NOTICE: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/05/20/shore-capital-reaffirms-sell-rating-for-astrazeneca-plc-azn-updated.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.